Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Luisa Ricciardi; Daniel Griscti Soler; Alessandra Bennici; Silvia Brunetto; Giovanni Pioggia; Sebastiano Gangemi

doi:10.3389/fphar.2022.858344

Frontiers in Pharmacology (Apr 2022)

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Luisa Ricciardi,
Daniel Griscti Soler,
Alessandra Bennici,
Silvia Brunetto,
Giovanni Pioggia,
Sebastiano Gangemi

Affiliations

Luisa Ricciardi: Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, University of Messina, Messina, Italy
Daniel Griscti Soler: Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, University of Messina, Messina, Italy
Alessandra Bennici: Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, University of Messina, Messina, Italy
Silvia Brunetto: Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, University of Messina, Messina, Italy
Giovanni Pioggia: Institute for Biomedical Reasearch and Innovation, National Research Council of Italy (IRIB-CNR), Messina, Italy
Sebastiano Gangemi: Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico “G. Martino”, University of Messina, Messina, Italy

DOI: https://doi.org/10.3389/fphar.2022.858344
Journal volume & issue: Vol. 13

Abstract

Read online

Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a major player in the pathogenesis of EGPA. In 2017 the Food and Drug Administration (FDA) approved mepolizumab, a humanized monoclonal antibody targeting interleukin 5 (IL-5) which reduces the production and survival of eosinophils, already used to treat severe eosinophilic asthma, for the management of EGPA. Benralizumab is a humanized monoclonal antibody that targets the IL-5 receptor and is indicated in the treatment of severe eosinophilic asthma.Case description: We describe the case of a young female with a positive history of severe eosinophilic asthma associated with EGPA, treated successfully with benralizumab.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords